Abbott's drug-eluting stent (DES) is the fourth on the US market after the Cordis Cypher stent, Boston Scientific's Taxus stent, and Medtronic's Endeavor stent. In two randomised clinical trials, Xience V demonstrated superiority over Boston Scientific's Taxus coronary stent system.
The clinical programme for Xience V includes long-term data from a total of 1,362 patients enrolled in the SPIRIT I, SPIRIT II and SPIRIT III trials, as well as continued access and post-approval programs that will enroll more than 14,000 Xience V patients.
Latest Articles
Abbott's drug-eluting stent (DES) is the fourth on the US market after the Cordis Cypher stent, Boston Scientific's Taxus stent, and Medtronic's Endeavor...
